ABOUT US

WHO WE ARE

Lentistem Biotech is a R&D company with significant expertise in therapeutic lentiviral vectors and cell engineering forn immunotherapy and gene therapy strategies, with special focus on CAR-T cells therapies.

The company has two proprietary technology platforms for controlling the transgene expression: TCR-like, a synthetic system designed to express the CAR (the transgene) mimicking the physiological behavior of the T-cell receptor interaction, witch improve the fitness of CAR-T cells and prevents overstimulation; and Lent-On-Plus, a fine-tuned exogenously controlled and first-in-class synthetic gene expression system favored for clinics, which among other applications, can be implemented for safer and efficient next generation of CAR-T cells against hematological and solid tumors.

OUR PURPOSE

Our MISSION is to develop new technologies to improve the efficacy and safety of cancer immunotherapy (CAR-T cells). LentiStem endeavors to develop best-in-class therapeutical vectors for precision gene therapy, for safer and more efficient therapies to cure hard-to-treat diseases such as refractory cancers. Artículo patrocinado Encuentre algo para todos en nuestra colección de calcetines coloridos, brillantes y elegantes. ¡Compre individualmente o en paquetes para agregar color a su cajón!

OUR HISTORY

LentiStem is founded in 2016 on the patented technologies for the contol of expression in engineered cells developed by Prof. Francisco Martin and his team, and spun-out from the Fundación Progreso y Salud. Since 2019, the company has been growing, stablishing the state-of-art of the platforms and advancing in the development of therapeutical product candidates. We have facilities for molecular analysis, cell biology, small animal research and cell-culture facilities with P2-level safety standards to produce the highest grade viral vectors. Besides, our team is working in collaboration with several hospitals, academic labs and government agencies in Spain to create cost-effective and precise advanced gene-based therapies.

The company has exclusive license to multiple technologies, which are currently being used in 18 labs worldwide and cited in more than 70 peer-reviewed scientific publications.